Funding
This work was supported by the Australian Research Council (ARC; CE140100011), the National Health and Medical Research Council, Australia (NHMRC 1113293), AIFA research grant (CFA and JAT, 2021); NHMRC investigator grant (JAT, 1139902). DIG was supported by an NHMRC Senior Principal Research Fellowship (1117766). DIG has also served as a paid member of an advisory committee, and shareholder, for Avalia Immunotherapies.